Inge Thulin Elected to Merck Board of Directors
January 24, 2018 7:00 am ET
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Inge Thulin, chairman of the board, president and
chief executive officer of 3M, will join the company’s board of
directors effective March 1, 2018. Mr. Thulin will stand for election
with the company’s other directors in connection with Merck’s Annual
Meeting of Shareholders on May 22, 2018. With the addition of Mr.
Thulin, the Merck board will include 14 members.
“We are pleased to add Mr. Thulin to the Merck board and look forward to
benefiting from his extensive experience as a global leader of an
innovative and science-based company,” said Kenneth C. Frazier, chairman
and chief executive officer, Merck.
Mr. Thulin is chairman of the board, president and chief executive
officer of 3M, a company that applies science in collaborative ways to
improve lives and create solutions to global problems. 3M has also been
widely recognized for its commitment to sustainability and diversity.
Mr. Thulin began his career with 3M in Europe in 1979 and since then has
assumed several key roles of increasing responsibility, most recently
serving as chief operating officer prior to his current role.
Mr. Thulin earned degrees in economics and marketing from the University
of Gothenburg in Sweden. He is a National Committee on U.S.-China
Relations Honoree, has received the Peter G. Peterson Business
Statesmanship Award from the Committee for Economic Development, the
Lucia Trade Award from the Swedish-American Chamber of Commerce and the
Hendrickson Medal for Ethical Leadership. Most recently, Mr. Thulin was
honored by Junior Achievement of The Upper Midwest, Inc. as a 2016
Business Hall of Fame Laureate.
About Merck
For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
visit www.merck.com
and connect with us on Twitter,
Facebook,
YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2016 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Merck
Media:
Tracy Ogden, 908-740-1747
or
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898
